Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
暂无分享,去创建一个
Axel Hoos | Jedd D. Wolchok | J. Wolchok | F. Hodi | M. Maio | C. Lebbé | S. O’Day | O. Hamid | J. Weber | G. Nichol | A. Hoos | S. Hodi | Omid Hamid | Michele Maio | Celeste Lebbé | Rachel Humphrey | R. Humphrey | M. Binder | F. Stephen Hodi | Jeffrey S. Weber | Michael Binder | Steven O'Day | Oliver Bohnsack | Geoffrey Nichol | O. Bohnsack | S. O'Day | Michael Binder | Stephen F. Hodi
[1] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[2] M. Maio,et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases , 2009, Cancer Immunology, Immunotherapy.
[3] S. O’Day,et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. Wolchok,et al. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. , 2008, The oncologist.
[5] R. Tuma. New response criteria proposed for immunotherapies. , 2008, Journal of the National Cancer Institute.
[6] M. Mihm,et al. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS , 2008, Nature Clinical Practice Oncology.
[7] H. Pehamberger,et al. Efficacy and safety of ipilimumab induction and maintenance dosing in patients with advanced melanoma who progressed on one or more prior therapies , 2008 .
[8] H. Pehamberger,et al. Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody , 2008 .
[9] G. Linette,et al. Dose effect of ipilimumab in patients with advanced melanoma: Results from a phase II, randomized, dose-ranging study , 2008 .
[10] A. Kubo,et al. Is response rate or stable disease rate a surrogate endpoint for survival in the treatment of advanced non-small cell lung cancer using epidermal growth factor receptor tyrosine kinase inhibitors? , 2008 .
[11] O. Hamid,et al. Safety and efficacy of ipilimumab with or without prophylactic budesonide in treatment-naive and previously treated patients with advanced melanoma , 2008 .
[12] J. Wolchok,et al. Antitumor response and new lesions in advanced melanoma patients on ipilimumab treatment , 2008 .
[13] D. Neuberg,et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients , 2008, Proceedings of the National Academy of Sciences.
[14] Hans-Peter Sinn,et al. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast , 2008, Breast Cancer Research.
[15] F. Hodi,et al. Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma , 2007 .
[16] S. O’Day,et al. The efficacy and safety of ipilimumab (MDX-010) in patients with unresectable stage III or stage IV malignant melanoma , 2007 .
[17] Drew M. Pardoll,et al. Immunostimulatory monoclonal antibodies for cancer therapy , 2007, Nature Reviews Cancer.
[18] A. Eggermont,et al. A clinical development paradigm for cancer vaccines and related biologics. , 2007, Journal of immunotherapy.
[19] S. Steinberg,et al. Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. , 2006, Blood.
[20] Martin Hutchings,et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. , 2006, Blood.
[21] D. Speiser,et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] A. Eggermont,et al. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE‐3 protein in patients with detectable metastatic melanoma , 2005, International journal of cancer.
[23] S. Rosenberg,et al. Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study , 2005, Annals of Surgical Oncology.
[24] S. Rosenberg,et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Mark J Ratain,et al. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] M. Christian,et al. [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.
[27] E. L. Calhoon. Immune therapy of cancer. , 1988, The Journal of the Oklahoma State Medical Association.
[28] M. Palmer,et al. WHO Handbook for Reporting Results of Cancer Treatment , 1982, British Journal of Cancer.
[29] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.